ArticleRheumatic diseases clinics of North America2010
A multitude of kinases--which are the best targets in treating rheumatoid arthritis?
Article in Rheumatic diseases clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Dual host and pathogen targeting by MEK1/2 inhibitors.Infection and immunity · 2026Review
- YWHAH Genetic Variants are Associated with Increased Hypoxia Inducible Factor-1α/Vascular Endothelial Growth Factor in Egyptian Rheumatoid Arthritis Patients.Biochemical genetics · 2022Article
- Article
- Small tumor necrosis factor receptor biologics inhibit the tumor necrosis factor-p38 signalling axis and inflammation.Nature communications · 2018Article
- Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition.Science signaling · 2018Article
- Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation.Nature chemical biology · 2017Article
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.Drug design, development and therapy · 2016Review
- Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.British journal of pharmacology · 2015Article
- Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis.PloS one · 2015Article
- Genetic and pharmacologic inhibition of Tpl2 kinase is protective in a mouse model of ventilator-induced lung injury.Intensive care medicine experimental · 2014Article
- Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Clinical and experimental immunology · 2014Review
- Emerging cell and cytokine targets in rheumatoid arthritis.Nature reviews. Rheumatology · 2014Review
- Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions.PloS one · 2014Article
- Review
- Development of polymeric nanocarrier system for early detection and targeted therapeutic treatment of peri-implant osteolysis.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2013Article
- Development of macromolecular prodrug for rheumatoid arthritis.Advanced drug delivery reviews · 2012Review
- A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.British journal of pharmacology · 2012Review
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.Arthritis research & therapy · 2011Article
- Induction of immune tolerance in the treatment of rheumatoid arthritis.Nature reviews. Rheumatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Small-molecule kinase inhibitors are increasingly taking center stage in the quest for new drugs for the treatment of rheumatoid arthritis (RA). By targeting kinases, small-molecule inhibitors can exert potent anti-inflammatory and immunomodulatory effects; the success of small-molecule kinase inhibitors in the treatment of cancer has spurred efforts to identify kinases that could be targeted for the treatment of chronic inflammatory disorders, such as RA. Although many kinase inhibitors have proved efficacious in the treatment of inflammatory arthritis in animals few have been tested in RA clinical trials. This article discusses the challenges and progress in the pursuit of small-molecule kinase inhibitors for RA, including lessons learned from the failure of erstwhile frontrunner inhibitors and the promise of inhibitors making their debut on the RA stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.